Continuous therapy in multiple myeloma

How important do you think continuous therapy is as opposed to fixed duration therapy in relapsed/refractory multiple myeloma? In your practice, what strategy is used to keep patients on long term therapy?

Dr Guy Pratt discusses the importance of continuous therapy as opposed to fixed duration therapy in relapsed/refractory multiple myeloma and strategies for keeping patients on long term therapy.

The views expressed in this video are those of the speaker.

To view this expert’s biography please visit the Myeloma Hub Faculty page.

UK/NP/1806/0035ad - August 2018

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.